Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Current Assets (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Current Assets for 3 consecutive years, with $112.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 40.27% to $112.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $112.7 million, a 40.27% decrease, with the full-year FY2025 number at $112.7 million, down 40.27% from a year prior.
  • Current Assets was $112.7 million for Q4 2025 at Artiva Biotherapeutics, down from $129.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $188.6 million in Q4 2024 to a low of $49.7 million in Q2 2024.
  • A 3-year average of $128.8 million and a median of $139.3 million in 2025 define the central range for Current Assets.
  • Biggest YoY gain for Current Assets was 199.64% in 2025; the steepest drop was 40.27% in 2025.
  • Artiva Biotherapeutics' Current Assets stood at $79.8 million in 2023, then soared by 136.32% to $188.6 million in 2024, then plummeted by 40.27% to $112.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Current Assets are $112.7 million (Q4 2025), $129.5 million (Q3 2025), and $149.1 million (Q2 2025).